Paromomycin 250mg/5g vaginal cream
Requires a prescription from a doctor or prescriber
An oligosaccharide antibiotic produced by various streptomyces.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Paromomycin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 11 · 1985–2025
Showing the 50 most relevant studies, sorted by most relevant.
A. Musa, E. Khalil, A. Hailu, et al.
PLoS Neglected Tropical Diseases, 2012
A. Asilian, M. Davami
Clinical and Experimental Dermatology, 2006
D. Kim, H. Chung, J. Bleys, et al.
PLoS Neglected Tropical Diseases, 2009
Tareq Alshaikh, Mohammed Jihad, Awwad Jomaa
Sultan Qaboos University Medical Journal, 2025
- Leishmaniasis, Cutaneous
- Gentamicins
- Paromomycin
Cutaneous leishmaniasis (CL) is the most common protozoal skin infection worldwide. Multiple treatments for CL have been developed to address issues related to resistance, availability, and safety. Topical treatments have shown promise by reducing unnecessary systemic exposure and providing a viable local therapeutic option. A systematic review and meta-analysis were conducted of all literature published before 28 February 2025 through PubMed/MEDLINE, the Cochrane Library, and EBSCO, comparing topical paromomycin–gentamicin (PG) with topical paromomycin alone (PR). Two studies involving a total of 774 patients were included. Relative risks (RRs) from both studies were pooled using a fixed-effect meta-analysis. The meta-analysis showed no significant difference in the final clinical cure of the index lesion between PG and PR (RR = 1.030; 95% confidence interval [CI]: 0.950–1.117), nor in the rate of cure of all lesions (RR = 0.987; 95% CI: 0.909–1.072). No serious adverse events were reported. When treating CL topically, the addition of gentamicin to paromomycin does not confer additional benefit.
Abstract licence: CC BY-ND 4.0
Pashupati Pokharel, R. Ghimire, Pratik Lamichhane
Journal of Tropical Medicine, 2021
B. Arana, C. Mendoza, N. Rizzo, et al.
The American journal of tropical medicine and hygiene, 2001
A. Hailu, A. Musa, M. Wasunna, et al.
PLoS Neglected Tropical Diseases, 2010
R. Moradzadeh, P. Golmohammadi, H. Ashraf, et al.
Iranian Journal of Medical Sciences, 2019
A. Salah, H. Zakraoui, A. Zâatour, et al.
The American journal of tropical medicine and hygiene, 1995
Thakur Cp, T. Kanyok, A. Pandey, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
199 found
Half-life
Not available
Mechanism
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 875 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Plays a role in cell adhesion to the basement membrane and in the consequent activation of signaling transduction pathways. May play a role in cell fate determination and tissue morphogenesis. Acts as a PPP1R16B-dependent substrate of PPP1CA
PMID:12490704
The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell .
PMID:23636399 PMID:25901680 PMID:32669547
The male germ cell-specific ribosome displays a ribosomal polypeptide exit tunnel of distinct size and charge states compared with the classical ribosome (By similarity). It is responsible for regulating the biosynthesis and folding of a subset of male germ-cell-specific proteins that are essential for the formation of sperm (By similarity)
ATC A07AA06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Paromomycin
Additional database identifiers
Drugs Product Database (DPD)
8625
ChemSpider
145115
BindingDB
50240054
PDB
PAR
ZINC
ZINC000060183170
GenBank Gene Database
U36504
GenBank Protein Database
1022792
UniProt Accession
RS10_THET8
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6502
GenAtlas
RPSA
GeneCards
RPSA
GenBank Gene Database
J03799
UniProt Accession
RSSA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17976
GeneCards
RPL10L
GenBank Gene Database
AB063608
GenBank Protein Database
23491783
UniProt Accession
RL10L_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q415625), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.